Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China
These rw results show that while first-generation EGFR-TKIs are associated with numerically longer rwPFS and rwTTNTD relative to chemoradiotherapy alone in Chinese patients with unresectable stage III EGFR-mutated NSCLC, there remains an unmet need to prolong survival.
Authors
- Y. Kim
- F. Nasirova
- XingYa Li
- Changchun Wang
- Yong Liang
- Ken Chen
- Shun Lu
- Zheng Yin
Institutions
- Shanghai Chest Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- AstraZeneca (France) (FR)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Canada) (CA)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1007/s12325-025-03488-x
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00